Moody Aldrich Partners’s Blueprint Medicines BPMC Stock Holding History

Moody Aldrich Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,331	Closed	-$1.98M	–	182
2025 Q1	$1.98M	Buy	+22,331	New	+$2.18M	0.41%	86
2023 Q1	–	Sell	-17,489	Closed	-$766K	–	160
2022 Q4	$766K	Sell	17,489 -697	-4%	-$33.4K	0.16%	119
2022 Q3	$1.2M	Buy	+18,186	New	+$1.17M	0.25%	108
2020 Q1	–	Sell	-18,522	Closed	-$1.48M	–	136
2019 Q4	$1.48M	Sell	18,522 -736	-4%	-$55.1K	0.31%	95
2019 Q3	$1.42M	Buy	+19,258	New	+$1.66M	0.38%	85

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Moody Aldrich Partners's BPMC Position: Q2 2025 in Review

Moody Aldrich Partners sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 22,331 shares — an estimated $1.98M sold.

Moody Aldrich Partners first reported a position in BPMC in Q3 2019 and held it in 5 quarters. The position peaked at $1.98M in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Moody Aldrich Partners reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Moody Aldrich Partners sold 22,331 Blueprint Medicines shares in Q2 2025, an estimated $1.98M.
Moody Aldrich Partners first reported a position in Blueprint Medicines in Q3 2019 and held it in 5 quarters.
Moody Aldrich Partners's Blueprint Medicines position peaked at $1.98M in Q1 2025.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Moody Aldrich Partners's 13F filing for Q2 2025, filed 4 Aug 2025.